Abstract
目的
探讨活性氧和铁死亡在丙酮醛诱导小鼠胚胎成骨细胞(MC3T3-E1)损伤中是否存在相互作用。
方法
应用丙酮醛损伤MC3T3-E1细胞建立模拟糖尿病骨质损伤的细胞模型。应用细胞计数试剂盒-8(CCK-8)测定MC3T3-E1细胞的存活率;罗丹明123染色荧光显微镜照相法测定线粒体膜电位;双氯荧光素(DCFH-DA)荧光显微镜照相法检测胞内活性氧水平;碱性磷酸酶试剂盒检测定碱性磷酸酶活性;茜素红染色观察成骨细胞晚期标志物-矿化结节的形成;铁离子试剂盒检测铁离子水平;Western blot检测成骨细胞的抑制铁死亡的标志蛋白谷胱甘肽过氧化物酶4(GPX4)的表达水平。
结果
0.6 mmol/L丙酮醛处理MC3T3-E1细胞24 h可明显减少GPX4的表达(P < 0.001),同时可使胞内铁离子浓度升高,细胞存活率降低,线粒体膜电位丢失,胞内活性氧水平升高,碱性磷酸酶活性降低和矿化结节减少(P < 0.001)。应用2 mmol/L活性氧清除剂N-乙酰半胱氨酸和丙酮醛共处理MC3T3-E1细胞24 h可增加GPX4的表达(P < 0.01),应用4 μmol/L铁死亡抑制剂铁抑素-1与丙酮醛共处理成骨细胞24 h可使胞内活性氧水平降低(P < 0.001);应用N-乙酰半胱氨酸或铁抑素-1与丙酮醛共处理成骨细胞24 h均能对抗丙酮醛引起的上述其他细胞损伤(P < 0.001)。
结论
活性氧与铁死亡通路相互作用在丙酮醛引起MC3T3-E1成骨细胞损伤中起重要的作用。
Keywords: 活性氧, 铁死亡, 丙酮醛, 成骨细胞, 糖尿病合并骨质疏松症
Abstract
Objective
To explore the interaction between reactive oxygen species (ROS) and ferroptosis in methylglyoxalinduced injury of mouse embryonic osteoblasts (MC3T3-E1 cells).
Methods
MC3T3-E1 cells were treated with methylglyoxal to establish a cell model of diabetic osteoporosis. CCK-8 assay was used to detect the viability of MC3T3-E1 cells. Rhodamine 123 staining followed by photofluorography was used to examine mitochondrial membrane potential (MMP). The intracellular ROS level was detected by 2', 7'-dichlorodihydrofluorescein diacetate staining with photofluorograph. Alkaline phosphatase (ALP) activity in the cells was detected using an ALP kit, the number of mineralized nodules was determined with alizarin red S staining, and the level of iron ions was detected using a detection kit. The expression level of glutathione peroxidase 4 (GPX4, a marker protein that inhibits ferroptosis) in the osteoblasts was determined using Western blotting.
Results
Treatment of MC3T3-E1 cells with 0.6 mmol/L methylglyoxal for 24 h significantly inhibited the expression level of GPX4 (P < 0.001), increased intracellular iron ion concentration, decreased the cell viability, increased the loss of MMP and intracellular ROS level, decreased both ALP activity and the number of mineralized nodules in the cells (P < 0.001). Co-treatment of MC3T3-E1 cells with 2 mmol/L N-acetylcysteine (NAC, a ROS scavenger) and methylglyoxal significantly increased the expression level of GPX4 (P < 0.01); co-treatment with 4 mmo/L FER-1 (a ferroptosis inhibitor) and methylglyoxal obviously decreased the intracellular ROS level (P < 0.001). Co-treatment of the cells either with NAC and methylglyoxal or with FER-1 and methylglyoxal attenuated methylglyoxal-induced injuries in the osteoblasts (P < 0.001).
Conclusion
The interaction between ROS and ferroptosis pathway plays an important role in methylglyoxal-induced injury of mouse embryonic osteoblasts.
Keywords: reactive oxygen species, ferroptosis, methylglyoxal, osteoblasts, diabetic osteoporosis
糖尿病合并骨质疏松症(DOP)是糖尿病的一种严重的并发症,是导致糖尿病患者躯体骨骼长期疼痛和功能障碍的主要原因,其致残和致死率较高,给社会和家庭造成巨大负担[1]。但是,DOP的发病机制复杂,给防治该病带来困难。因此深入探讨DOP的病理生理机制具有重要的临床意义。
目前已知的研究表明晚期糖基化终末产物(AGEs)(包括其前体MG)的堆积[2-3]、氧化应激反应[4]、高血糖毒性[5]和炎症反应[6]等机制可能参与DOP的发生。在糖尿病患者中,高血糖促进了MG的生成,能引起蛋白质和其他底物的快速修饰产生AGEs,并可能在DOP的发病机制中起重要作用[2, 7]。糖尿病患者血清中AGEs的前体MG浓度异常高,能诱发氧化应激,是引起包括骨质疏松在内的一系列糖尿病并发症的重要因素[2, 8]。Moraru等[9]通过产生和表征Glo1基因敲除果蝇来研究内源性MG升高的后果,发现MG增多会导致动物逐步出现2型糖尿病的核心特征:高血糖、胰岛素抵抗和肥胖。尽管MG升高可以再现T2DM表型,并可能引起骨质疏松,但是有关MG引起成骨细胞损伤的病理生理机制,特别是与铁死亡的关系如何尚未见报道。
铁死亡是一种依赖铁离子的脂质过氧化介导的调节性细胞死亡方式,在抗氧化剂-谷胱甘肽(GSH)存在下,GPX4具有独特的抑制脂质过氧化和保护细胞免受铁死亡的作用[10]。FER-1作为脂溶性抗氧化剂,可以缓解铁死亡。铁死亡在多种糖尿病并发症中的作用均有研究。近期更有学者研究提出,在2型糖尿病骨质疏松症小鼠中,高血糖可诱导铁死亡[11-12]。然而,铁死亡是否参与MG诱导的成骨细胞损伤,目前尚未明确。
ROS是糖尿病并发症的重要驱动因素之一,ROS可通过影响一些代谢通路,如AGEs及其受体轴,蛋白激酶C(PKC)等损伤微血管结构,继而引起并发症[13]。而AGEs本身也可产生ROS。此外,MG对抗氧化蛋白的修饰进一步促进ROS的生成[7]。值得注意的是,铁死亡与细胞内ROS增加密切相关[11]。有研究报道,抑制线粒体ROS可减轻高糖诱导的心肌细胞焦亡与铁死亡[14],但是,在MG损伤成骨细胞过程中,ROS与铁死亡关系如何,是否存在相互作用?目前尚不清楚。本实验应用MG作用小鼠胚胎成骨细胞(MC3T3-E1细胞)模拟构建DOP的细胞模型,并应用NAC和FER-1干预成骨细胞,旨在重点研究ROS和铁死亡在MG引起成骨细胞损伤中的作用及它们之间是否存在相互作用,对进一步阐述DOP的发病机制及防治DOP具有重要的理论意义和临床指导意义。
1. 材料和方法
1.1. 材料
MC3T3-E1细胞购自上海中科院细胞库;细胞计数试剂盒-8(CellCountingKit-8,CCK-8)由上海贝博生物科技有限公司提供;NAC、罗丹明123(rhodamine123,Rh123)和2',7'-二氯二氢荧光素二乙酯(DCFH-DA)(Sigma-Aldrich);抗GPX4抗体购(Abcam);碱性磷酸酶(ALP)活性测定试剂盒;铁抑制素-1(FER-1)(MedChemExpress);铁离子比色法检测试剂盒(北京普利莱基因技术有限公司);小鼠MC3T3-E1细胞成骨诱导分化培养基(赛业生物科技有限公司)。
1.2. 方法
1.2.1. MC3T3-E1细胞培养
含10%胎牛血清的培养基用于培养MC3T3-E1细胞,当细胞密度达到80%~ 90%时,进行传代及后续实验。
1.2.2. 实验分组
实验分为6组:(1)对照组:单独用α- MEM培养基处理MC3T3-E1细胞24 h;(2)MG组:用含0.6 mmol/L MG的α-MEM培养基处理细胞24 h;(3)FER-1+MG组:用含4 μmol/L FER-1与0.6 mmol/L MG的α-MEM培养基共同培养细胞24 h;(4)FER-1组:用含4 μmol/L FER-1的α-MEM培养基干预细胞24 h;(5)NAC+MG组:用含2 mmol/L NAC与MG的α-MEM培养基共同培养细胞24 h;(6)NAC组:用含2 mmol/L NAC的α-MEM培养基处理细胞24 h。
1.2.3. Western blot检测蛋白表达水平
于60 mm皿中培养成骨细胞,密度达标后给予不同处理;用预冷的PBS充分冲洗、吸干,加入裂解液后冰上作用30 min,冰上刮取皿中蛋白,4 ℃、12 000 r/min离心10 min,吸取离心后上清液,用BCA法计算各组上清液中蛋白的浓度。SDS-PAGE电泳分离各组蛋白并转移至PVDF膜上,5% 脱脂奶粉封闭1 h,加入抗GPX4抗体(1∶2000稀释);4 ℃摇床孵育过夜,冷TBST液充分漂洗膜3次,10 min/次;II抗(1∶5000稀释)于4 ℃孵育2 h,TBST充分漂洗,利用发光试剂ECL显色,曝光,凝胶成像系统分析结果。实验重复3次。
1.2.4. CCK-8法测定细胞存活率
于96孔板培养成骨细胞,每个分组设4个复孔,根据不同分组处理后,PBS润洗,每孔分别加入90 µL α-MEM和10 µL CCK-8试剂,随后在37 ℃温箱中放置2 h,酶标仪测定450 nm波长的吸光度(A),计算出各组复孔的平均值后代入公式:细胞的相对活力(%)=A处理组/A对照组×100%。实验最少重复3次。
1.2.5. 线粒体膜电位(MMP)的测定
用6孔板培养成骨细胞,根据不同分组干预后,PBS润洗2~3次,每孔加入10 mg/L Rh123染色剂覆盖细胞,37 ℃培养45 min,再用PBS润洗3次,后用图像分析软件评估图片荧光强度的平均值(平均荧光强度MFI,反映线粒体膜电位的高低)。实验重复3次。
1.2.6. 细胞内ROS水平的检测
将成骨细胞种于6孔板,不同干预后,PBS润洗3次,每孔加入10 μmol/L的DCFH-DA染色液500 μL覆盖细胞,37 ℃培养箱中孵育35 min,PBS冲洗3次,每个分组的贴壁壁细胞于倒置荧光显微镜下随机拍照,应用Image J图像分析软件记录每张图片的平均荧光强度(MIF),实验重复3次。
1.2.7. ALP活性测定
按照不同实验分组干预成骨细胞,PBS润洗,加入成骨诱导液,并且每3 d更换一次,成骨诱导液培养7 d,每孔加入适量裂解液充分裂解30 min,13 000 r/min、4 ℃离心10 min,取上清,对多实验组分别按试剂盒说明加入相应的试剂,在520 nm波长时测每个组的吸光度(A520 nm),根据公式计算ALP活性。本试验重复3次。
1.2.8. 钙化结节的检测
将细胞种于6孔板种,加不同干预24 h后,PBS充分润洗后加入成骨诱导液,3 d换1次分化液,培养21 d,PBS润洗,每孔加入4 %多聚甲醛固定10 min,随后覆盖茜素红染液避光反应45 min,PBS充分冲洗后,倒置显微镜下观察橙红色钙化结节。为了定量分析矿化区域,将染色样品溶解在含10%十六烷基氯化吡啶的10 mmol/L磷酸钠水溶液中,测量吸光度A620 nm。试验重复3次。
1.2.9. 铁离子检测
按照实验分组给与不同干预后,加入裂解液置于摇床裂解2 h后收集不同分组标本;按照铁离子比色法检测试剂盒操作说明,将裂解的样品与混液A混匀,60 ℃孵育1 h,冷却至室温后加入铁离子检测试剂,常温孵育30 min,在波长为550 nm处测定吸光度(A550 nm),根据标准曲线计算铁离子浓度。重复实验3次。
1.3. 统计学处理
采用SPSS 25.0软件统计分析实验结果,实验数据均以均数±标准差表示;多组间均数的比较运用单因素方差分析方法,两组间的比较用LSD检验,当P < 0.05时认为差异有统计学意义。
2. 结果
2.1. MG呈剂量依赖性降低MC3T3-E1细胞存活率
不同浓度(50~800 μmol/L)MG处理MC3T3-E1细胞24 h,可使细胞存活率明显下降,且呈剂量依赖的趋势(P < 0.001,图 1)。其中600 μmol/L MG作用MC3T3- E1细胞24 h后,MC3T3-E1细胞存活率降至(49.06± 4.68)%,因此,本研究选择600 μmol/L MG作为后续实验的作用浓度。
1.

不同浓度丙酮醛对成骨细胞存活率的影响
Effects of methylglyoxal at different concentrations (0-800 μmol/L) for 24 h on viability of MC3T3-E1 cells (Mean±SD, n=3). **P < 0.01 vs control group.
2.2. ROS清除剂和铁死亡抑制剂减轻MG抑制MC3T3- E1细胞GPX4表达
与对照组相比,600 μmol/L MG作用于MC3T3-E1细胞24 h,GPX4显著下降(P < 0.001)(图 2A和B);应用2 mmol/L NAC与MG共同干预MC3T3-E1细胞24 h,可明显增加GPX4表达,与MG组相比较,差异具有统计学意义(P < 0.01);NAC本身对成骨细胞GPX4的基础表达水平无明显影响(图 2A、C)。另一方面,用4 μmol/L FER-1与MG共处理细胞24 h后可对抗MG对成骨细胞GPX4表达的抑制作用,与MG组相比,差异显著(P < 0.001);单纯FER-1对GPX4的基础表达无明显影响(图 2B、D)。
2.

ROS清除剂与铁死亡抑制剂减轻丙酮醛抑制成骨细胞GPX4表达
NAC (an inhibitor of ROS) and FER-1 (an inhibitor of ferroptosis) mitigate methylglyoxal (MG)-induced down-regulation of GPX4 in MC3T3-E1 osteoblasts. A, B: Western blots of GPX4 and β-actin in MC3T3-E1 cells. C, D: GPX4 protein levels normalized by β-actin levels (Mean±SD, n=3). ##P < 0.01 vs control group; **P < 0.01vs MG group.
2.3. NAC和FER-1抑制MG诱导的铁离子增多
在铁死亡过程中,铁离子以二价铁的形式大量存在,从而通过芬顿反应启动脂质体过氧化,检测细胞内铁离子水平有助于我们判断铁死亡。与对照相比,MG处理成骨细胞24 h铁离子明显增多(图 3,P < 0.001);在MG作用同时,加用2 mmol/L NAC处理成骨细胞24 h,铁离子明显减少,与MG组比较,差异有统计学意义(P < 0.001)。另外,与MG组比较,MG与4 μmol/L FER-1共处理MC3T3-E1细胞24 h,铁离子水平也明显减少(P < 0.001)。单独NAC或FER-1干预对铁离子基础水平未见明显影响。
3.

NAC与FER-1抑制丙酮醛诱导的成骨细胞铁离子增多
NAC and FER-1 inhibit methylglyoxal (MG) -induced increase of iron ions in MC3T3-E1 osteoblasts (Mean±SD, n=3). ##P < 0.01 vs control group; **P < 0.01 vs MG group.
2.4. NAC和FER-1对抗MG诱导的线粒体损伤
MG干预MC3T3-E1细胞24 h,成骨细胞内Rh123的MFI值(反映MMP水平)从(25.15±0.41)%(control组)降至(5.8±1.96)%,两者差异有统计学意义(P < 0.001)。但是,应用2 mmol/L NAC与MG共同处理成骨细胞24 h可减少MMP的丢失,使MFI升至(18.12± 1.74)%,与MG组相比,差异具有统计学意义(P < 0.001,图 4A、C)。与NAC的保护作用相类似,4 μmol/L FER-1与MG共处理成骨细胞24 h也能减少MMP的丢失,与MG组相比,差异具有统计学意义(P < 0.001,图 4B、D)。单独NAC或FER-1处理成骨细胞对MMP无明显影响。
4.

NAC与FER-1抑制MG诱导的成骨细胞线粒体膜电位丢失
NAC and FER-1 inhibit methylglyoxal (MG) -induced loss of mitochondrial membrane potential (MMP) in MC3T3-E1 osteoblasts. A, B: Images of mitochondrial membrane potential (Green, original magnification: ×40). C, D: Quantitative analysis of fluorescence intensity of MMP (Mean±SD, n=3). ##P < 0.01 vs control group; **P < 0.01 vs MG group.
2.5. NAC和FER-1减轻MG对成骨细胞ALP活性的抑制
MG作用MC3T3-E1细胞24 h可使ALP活性明显下降(P < 0.001);NAC或FER-1与MG共处理MC3T3-E1细胞24 h可对抗MG对ALP活性的抑制作用(P < 0.001),使ALP活性升高,与MG组相比,差异具有统计学意义(P均 < 0.001);单独2 mmol/L NAC或4 μmol/L FER-1干预对MC3T3-E1细胞ALP活性未见明显影响(图 5)。
5.

NAC与FER-1抑制MG诱导的成骨细胞ALP活性降低
NAC and FER-1 attenuate methylglyoxal (MG)-induced reduction of ALP activity in MC3T3-E1 osteoblasts (Mean±SD, n=3). ##P < 0.01 vs control group; **P < 0.01 vs MG group.
2.6. NAC和FER-1对抗MG诱导的成骨细胞矿化结节减少
与对照组相比,MG组MC3T3-E1细胞的矿化结节数量明显减少(图 6,P < 0. 001),FER-1或NAC与MG共处理MC3T3-E1细胞24 h,分别明显地减轻MG对矿化结节生成的抑制作用,使矿化结节数量显著增多,与MG组比较,分别具有统计学意义(P < 0.001)。单独NAC或FER-1处理对矿化结节的生成无明显影响(图 6)。
6.

NAC与FER-1抑制丙酮醛诱导的成骨细胞矿化结节减少
NAC and FER-1 ameliorate methylglyoxal (MG) -induced decrease of mineralization capacity in MC3T3-E1 osteoblasts. A: Images of mineralized nodules (red, ×100). B: Quantitative analysis of the mineralized area (Mean±SD, n=3). ##P < 0.01 vs control group; **P < 0.01vs MG group.
2.7. NAC和FER-1抑制MG对成骨细胞内ROS生成的促进作用
MG干预MC3T3-E1细胞24 h,使DCFH-DA染色的贴壁成骨细胞内MFI(为ROS水平的指标)明显升高,与对照组比较,差异具有统计学意义(图 7,P < 0.001)。另外,应用2 mmol/L NAC与MG共同干预成骨细胞24 h可明显减少ROS的生成(P < 0.001,图 7A、C)。与NAC的保护作用相类似,与MG组相比,4 μmol/L FER-1与MG共处理成骨细胞24 h也能明显减少ROS的生成(P < 0.001,图 7B、D),单独NAC或FER-1处理MC3T3- E1细胞24 h对胞内ROS的基础水平无明显影响。
7.

NAC和FER-1抑制丙酮醛对成骨细胞内ROS生成的促进作用
NAC and FER-1 ameliorate methylglyoxal (MG)-induced increase of intracellular ROS production in MC3T3-E1 osteoblasts. A, B: Images of reactive oxygen species (green, ×100). C, D: Quantitative analysis of fluorescence intensity of ROS (Mean±SD, n=3). ##P < 0.01 vs control group; **P < 0.01vs MG group.
3. 讨论
目前,学者们认为,糖尿病骨质疏松(DOP)是糖尿病的并发症之一,其发病机制较复杂,其中高血糖引起晚期糖基化终末产物(AGEs)增多是导致DOP发生的一个重要病例生理机制。AGEs可作用于多种细胞,与细胞表面的受体(RAGE)结合,产生多种炎症因子如IL-1、IL-6和肿瘤坏死因子α(TNF-α)等,促进破骨细胞的分化成熟与增强破骨细胞活性,从而增加骨吸收,并能通过激活丝裂原蛋白激酶(MAPK)通路促进成骨细胞调亡,减少骨形成[1]。而MG是AGEs的前体,不仅可增加AGEs的生成,也可促进氧化应激及炎症[2]。Moraru等[9]发现果蝇的内源性MG升高可以再现T2DM表型,临床研究也证实,DM患者血清中MG浓度异常升高,能诱发氧化应激,可能是引起包括骨质疏松在内的糖尿病并发症的重要因素[2, 8]。Suh等[15]发现MG可引起MC3T3-E1成骨细胞死亡,胞内ROS生成增多,线粒体损伤及炎症反应。同样本研究在应用MG处理MC3T3-E1成骨细胞拟建立模拟DOP的细胞模型中也证实,MG可引起MC3T3-E1成骨细胞产生多种损伤,表现为细胞存活率降低,胞内ROS生成增多,MMP丢失。重要的是,我们新观察到MG能引起MC3T3-E1细胞出现铁死亡及引起铁离子浓度升高,ALP活性降低,矿化结节形成减少,进一步丰富了suh等[15-16]的实验结果,并提示铁死亡及铁离子调控障碍可能在MG引起的成骨细胞损伤中起重要作用。这是一个新颖的实验结果。
铁死亡是一种铁离子和ROS依赖性的细胞死亡类型之一,并被证实在多种疾病,例如癌症[17-18]、神经退行性疾病[19-21]和肾脏损伤[22-23]等疾病的发病机制中起着重要的作用。值得注意的是,铁死亡在生物化学、形态学和遗传学方面不同于凋亡、自噬、坏死及其他类型的细胞死亡,其特征是胞内铁离子和脂质ROS堆积、线粒体膜密度增加和线粒体蜷缩[24]。近年,有研究发现铁死亡参与与糖尿病相关的组织器官损伤的病理过程,如糖尿病心肌病[25]、糖尿病内皮功能障碍[26]、糖尿病肾病[27]、糖尿病认知功能障碍[28]等,并且已引起学者们的高度重视。但是,迄今为止,铁死亡是否参与DOP发生鲜有报道。2020年,Ma等[12]证实,高糖能引起MC3T3-E1成骨细胞发生铁死亡、细胞毒性和脂质过氧化等损伤。2021年,Wang等[11]在2型糖尿病DOP大鼠及高糖处理的人成骨细胞株(HFOB)证实,高糖能引起成骨细胞发生铁死亡。同样的,本研究首次证实,作为糖代谢的中间产物MG也能引起MC3T3-E1成骨细胞发生铁死亡及铁离子浓度升高,提示MG可能是高糖引起成骨细胞发生铁死亡的重要机制之一。为了进一步证实铁死亡在MG引起DOP中的作用,我们应用FER-1与MG共处理MC3T3-E1成骨细胞,结果表明,FER-1能明显地减轻MG对GPX4表达的抑制作用(反映铁死亡减少),使铁离子浓度降低,并能对抗MG引起的上述多种损伤,表明铁死亡可介导MG引起的成骨细胞损伤,它可以做为防治DOP的一个新靶点。
在DOP发病过程中,糖氧化的每一个步骤均可产生ROS,MG诱导产生的ROS不仅能损伤线粒体,且进一步促进ROS生成与线粒体损伤[16]。本研究也证实MG能增加胞内ROS生成,并引起MMP明显丢失,这与前文[2, 15]的报道相一致。有研究报道,在H9C2心肌细胞中,通过抑制线粒体ROS和炎症小体可减轻高糖诱导的焦亡和铁死亡[14]。NaveenKumar等[29]证实血红蛋白降解产物血红素可通过ROS和脂质过氧化诱导血小板铁死亡。Wen等[30]发现18-β-甘草次酸可促进ROS的产生,并加剧脂质过氧化从而引发乳腺癌细胞的铁死亡。同样的,本研究也在MG诱导的成骨细胞损伤模型上发现ROS可诱导铁死亡,及铁离子增多,支持以上结论。但值得注意的是,目前尚未有研究报道通过铁死亡对ROS的影响。由于铁死亡是铁离子和ROS依赖性的,为了进一步确定在MG损伤成骨细胞的过程中,ROS和铁死亡之间是否存在相互调控的关系,因此,本研究首先观察了ROS清除剂(NAC)对MG上调成骨细胞铁离子水平及促进铁死亡的影响。结果表明NAC能明显地抑制MG增加铁离子水平及铁死亡的作用,提示铁死亡是ROS依赖的。这与NaveenKumar等[29-30]报道的结果相一致。另外,我们观察到NAC也能对抗MG引起成骨细胞的其他损伤,使细胞存活率升高,MMP丢失减少,ALP活性与矿化结节生成数量增多。表明MG通过增加ROS生成是诱发成骨细胞多种损伤的一条重要途径。接着我们研究新发现,FER-1能显著地抑制MG对ROS生成的促进作用及其他损伤,提示铁死亡可促进ROS的生成。
综上所述,本文证实,ROS/铁死亡通路参与MG诱导的DOP,并推测ROS和铁死亡通路之间可能存在相互调控作用,共同介导MG引起MC3T3-E1成骨细胞损伤,这为深入阐明MG在DOP发生发展中的病理生理作用及其机制提供了新颖的实验依据,具有创新性。
Biography
冯苑仪,在读硕士研究生,E-mail:1134485615@qq.com
Funding Statement
广东省自然科学基金(2015A030313872);广州市卫生和计划生育科技项目(20181A011114)
References
- 1.冯 正平, 邓 华聪. 糖尿病性骨质疏松发病机制的研究进展. 中国骨质疏松杂志. 2012;18(3):281–5. doi: 10.3969/j.issn.1006-7108.2012.03.022. [冯正平, 邓华聪. 糖尿病性骨质疏松发病机制的研究进展[J]. 中国骨质疏松杂志, 2012, 18(3): 281-5.] [DOI] [Google Scholar]
- 2.Lee K M, Lee C Y, Zhang G, et al. The dataset of methylglyoxal activating p38 and p44/42 pathway in osteoclast. Data Brief. 2019;26:104500. doi: 10.1016/j.dib.2019.104500. [Lee K M, Lee C Y, Zhang G, et al. The dataset of methylglyoxal activating p38 and p44/42 pathway in osteoclast[J]. Data Brief, 2019, 26: 104500.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Cheng YZ, Yang SL, Wang JY, et al. Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. Life Sci. 2018;205:184–92. doi: 10.1016/j.lfs.2018.04.042. [Cheng YZ, Yang SL, Wang JY, et al. Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway[J]. Life Sci, 2018, 205: 184-92.] [DOI] [PubMed] [Google Scholar]
- 4.Callaghan MJ, Ceradini DJ, Gurtner GC. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. http://www.onacademic.com/detail/journal_1000034868311010_50a4.html. Antioxid Redox Signal. 2005;7(11/12):1476–82. doi: 10.1089/ars.2005.7.1476. [Callaghan MJ, Ceradini DJ, Gurtner GC. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function[J]. Antioxid Redox Signal, 2005, 7(11/12): 1476-82.] [DOI] [PubMed] [Google Scholar]
- 5.Robertson R P, Harmon J, Tran P O, et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(Suppl 1):S119–24. doi: 10.2337/diabetes.53.2007.s119. [Robertson R P, Harmon J, Tran P O, et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes[J]. Diabetes, 2004, 53 (Suppl 1): S119-24.] [DOI] [PubMed] [Google Scholar]
- 6.Lian D, Yuan H, Yin X, et al. Puerarin inhibits hyperglycemiainduced inter-endothelial junction through suppressing endothelial Nlrp3 inflammasome activation via ROS-dependent oxidative pathway. Phytomedicine. 2019;55:310–9. doi: 10.1016/j.phymed.2018.10.013. [Lian D, Yuan H, Yin X, et al. Puerarin inhibits hyperglycemiainduced inter-endothelial junction through suppressing endothelial Nlrp3 inflammasome activation via ROS-dependent oxidative pathway[J]. Phytomedicine, 2019, 55: 310-9.] [DOI] [PubMed] [Google Scholar]
- 7.Ramasamy R, Yan SF, Schmidt AM. Methylglyoxal comes of AGE. Cell. 2006;124(2):258–60. doi: 10.1016/j.cell.2006.01.002. [Ramasamy R, Yan SF, Schmidt AM. Methylglyoxal comes of AGE [J]. Cell, 2006, 124(2): 258-60.] [DOI] [PubMed] [Google Scholar]
- 8.董 小变, 吴 娟, 庄 晓东, et al. N-乙酰半胱氨酸对抗丙酮醛引起的心肌细胞损伤. 中国病理生理杂志. 2016;32(3):398–404. doi: 10.3969/j.issn.1000-4718.2016.03.003. [董小变, 吴娟, 庄晓东, 等. N-乙酰半胱氨酸对抗丙酮醛引起的心肌细胞损伤[J]. 中国病理生理杂志, 2016, 32(3): 398-404.] [DOI] [Google Scholar]
- 9.Moraru A, Wiederstein J, Pfaff D, et al. Elevated levels of the reactive metabolite methylglyoxal recapitulate progression of type 2 diabetes. Cell Metab. 2018;27(4):926–34. doi: 10.1016/j.cmet.2018.02.003. [Moraru A, Wiederstein J, Pfaff D, et al. Elevated levels of the reactive metabolite methylglyoxal recapitulate progression of type 2 diabetes[J]. Cell Metab, 2018, 27(4): 926-34. e8.] [DOI] [PubMed] [Google Scholar]
- 10.Sun Y, Chen P, Zhai B, et al. The emerging role of ferroptosis in inflammation. Biomed Pharmacother. 2020;127:110108. doi: 10.1016/j.biopha.2020.110108. [Sun Y, Chen P, Zhai B, et al. The emerging role of ferroptosis in inflammation[J]. Biomed Pharmacother, 2020, 127: 110108.] [DOI] [PubMed] [Google Scholar]
- 11.Wang X, Ma H, Sun J, et al. Mitochondrial ferritin deficiency promotes osteoblastic ferroptosis via mitophagy in type 2 diabetic osteoporosis. Biol Trace Elem Res. 2022;200(1):298–307. doi: 10.1007/s12011-021-02627-z. [Wang X, Ma H, Sun J, et al. Mitochondrial ferritin deficiency promotes osteoblastic ferroptosis via mitophagy in type 2 diabetic osteoporosis[J]. Biol Trace Elem Res, 2022, 200(1): 298-307.] [DOI] [PubMed] [Google Scholar]
- 12.Ma H, Wang X, Zhang W, et al. Melatonin suppresses ferroptosis induced by high glucose via activation of the Nrf2/HO-1 signaling pathway in type 2 diabetic osteoporosis. http://www.ncbi.nlm.nih.gov/pubmed/33343809. Oxid Med Cell Longev. 2020;2020:9067610. doi: 10.1155/2020/9067610. [Ma H, Wang X, Zhang W, et al. Melatonin suppresses ferroptosis induced by high glucose via activation of the Nrf2/HO-1 signaling pathway in type 2 diabetic osteoporosis[J]. Oxid Med Cell Longev, 2020, 2020: 9067610.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Pickering RJ, Rosado CJ, Sharma A, et al. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clin Transl Immunology. 2018;7(4):e1016. doi: 10.1002/cti2.1016. [Pickering RJ, Rosado CJ, Sharma A, et al. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications [J]. Clin Transl Immunology, 2018, 7(4): e1016.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.王 佳慧, 梁 欢, 方 典, et al. 抑制线粒体活性氧自由基可减轻高糖诱导的心肌细胞焦亡和铁死亡. https://www.j-smu.com/CN/10.12122/j.issn.1673-4254.2021.07.03. 南方医科大学学报. 2021;41(7):980–7. doi: 10.12122/j.issn.1673-4254.2021.07.03. [王佳慧, 梁欢, 方典, 等. 抑制线粒体活性氧自由基可减轻高糖诱导的心肌细胞焦亡和铁死亡[J]. 南方医科大学学报, 2021, 41(7): 980-7.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Suh KS, Chon S, Choi EM. Luteolin alleviates methylglyoxalinduced cytotoxicity in osteoblastic MC3T3-E1 cells. Cytotechnology. 2016;68(6):2539–52. doi: 10.1007/s10616-016-9977-y. [Suh KS, Chon S, Choi EM. Luteolin alleviates methylglyoxalinduced cytotoxicity in osteoblastic MC3T3-E1 cells[J]. Cytotechnology, 2016, 68(6): 2539-52.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Suh KS, Chon S, Choi EM. Protective effects of honokiol against methylglyoxal-induced osteoblast damage. Chem Biol Interact. 2016;244:169–77. doi: 10.1016/j.cbi.2015.12.015. [Suh KS, Chon S, Choi EM. Protective effects of honokiol against methylglyoxal-induced osteoblast damage[J]. Chem Biol Interact, 2016, 244: 169-77.] [DOI] [PubMed] [Google Scholar]
- 17.Li B, Yang L, Peng X, et al. Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers. Biomed Pharmacother. 2020;130:110710. doi: 10.1016/j.biopha.2020.110710. [Li B, Yang L, Peng X, et al. Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers[J]. Biomed Pharmacother, 2020, 130: 110710.] [DOI] [PubMed] [Google Scholar]
- 18.Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35(6):830–49. doi: 10.1016/j.ccell.2019.04.002. [Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer[J]. Cancer Cell, 2019, 35(6): 830-49.] [DOI] [PubMed] [Google Scholar]
- 19.Chen X, Li D, Sun HY, et al. Relieving ferroptosis may partially reverse neurodegeneration of the auditory cortex. Febs J. 2020;287(21):4747–66. doi: 10.1111/febs.15266. [Chen X, Li D, Sun HY, et al. Relieving ferroptosis may partially reverse neurodegeneration of the auditory cortex[J]. Febs J, 2020, 287(21): 4747-66.] [DOI] [PubMed] [Google Scholar]
- 20.Reichert CO, de Freitas FA, Sampaio-Silva J, et al. Ferroptosis Mechanisms Involved in Neurodegenerative Diseases. Int J Mol Sci. 2020;21(22):8765. doi: 10.3390/ijms21228765. [Reichert CO, de Freitas FA, Sampaio-Silva J, et al. Ferroptosis Mechanisms Involved in Neurodegenerative Diseases[J]. Int J Mol Sci, 2020, 21(22): 8765.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Vitalakumar D, Sharma A, Flora SJS. Ferroptosis: a potential therapeutic target for neurodegenerative diseases. http://onlinelibrary.wiley.com/doi/10.1002/jbt.22830. J Biochem Mol Toxicol. 2021;35(8):e22830. doi: 10.1002/jbt.22830. [Vitalakumar D, Sharma A, Flora SJS. Ferroptosis: a potential therapeutic target for neurodegenerative diseases[J]. J Biochem Mol Toxicol, 2021, 35(8): e22830.] [DOI] [PubMed] [Google Scholar]
- 22.Guo L, Zhang T, Wang F, et al. Targeted inhibition of Rev-erbα/β limits ferroptosis to ameliorate folic acid-induced acute kidney injury. Br J Pharmacol. 2021;178(2):328–45. doi: 10.1111/bph.15283. [Guo L, Zhang T, Wang F, et al. Targeted inhibition of Rev-erbα/β limits ferroptosis to ameliorate folic acid-induced acute kidney injury [J]. Br J Pharmacol, 2021, 178(2): 328-45.] [DOI] [PubMed] [Google Scholar]
- 23.Zhao Z, Wu J, Xu H, et al. XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemia-reperfusion injury. Cell Death Dis. 2020;11(8):629. doi: 10.1038/s41419-020-02871-6. [Zhao Z, Wu J, Xu H, et al. XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemia-reperfusion injury[J]. Cell Death Dis, 2020, 11(8): 629.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Lee YS, Lee DH, Choudry HA, et al. Ferroptosis-induced endoplasmic Reticulum stress: cross-talk between ferroptosis and apoptosis. Mol Cancer Res. 2018;16(7):1073–6. doi: 10.1158/1541-7786.MCR-18-0055. [Lee YS, Lee DH, Choudry HA, et al. Ferroptosis-induced endoplasmic Reticulum stress: cross-talk between ferroptosis and apoptosis[J]. Mol Cancer Res, 2018, 16(7): 1073-6.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Li W, Li W, Leng Y, et al. Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic Reticulum stress. DNA Cell Biol. 2020;39(2):210–25. doi: 10.1089/dna.2019.5097. [Li W, Li W, Leng Y, et al. Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic Reticulum stress[J]. DNA Cell Biol, 2020, 39(2): 210-25.] [DOI] [PubMed] [Google Scholar]
- 26.Luo EF, Li HX, Qin YH, et al. Role of ferroptosis in the process of diabetes-induced endothelial dysfunction. World J Diabetes. 2021;12(2):124–37. doi: 10.4239/wjd.v12.i2.124. [Luo EF, Li HX, Qin YH, et al. Role of ferroptosis in the process of diabetes-induced endothelial dysfunction[J]. World J Diabetes, 2021, 12(2): 124-37.] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Wang Y, Bi R, Quan F, et al. Ferroptosis involves in renal tubular cell death in diabetic nephropathy. European J Pharmacol. 2020;888:173574. doi: 10.1016/j.ejphar.2020.173574. [Wang Y, Bi R, Quan F, et al. Ferroptosis involves in renal tubular cell death in diabetic nephropathy[J]. European J Pharmacol, 2020, 888: 173574.] [DOI] [PubMed] [Google Scholar]
- 28.Hao L, Mi J, Song L, et al. SLC40A1 mediates ferroptosis and cognitive dysfunction in type 1 diabetes. Neuroscience. 2021;463:216–26. doi: 10.1016/j.neuroscience.2021.03.009. [Hao L, Mi J, Song L, et al. SLC40A1 mediates ferroptosis and cognitive dysfunction in type 1 diabetes[J]. Neuroscience, 2021, 463: 216-26.] [DOI] [PubMed] [Google Scholar]
- 29.NaveenKumar SK, Hemshekhar M, Kemparaju K, et al. Hemininduced platelet activation and ferroptosis is mediated through ROSdriven proteasomal activity and inflammasome activation: Protection by Melatonin. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2303–16. doi: 10.1016/j.bbadis.2019.05.009. [NaveenKumar SK, Hemshekhar M, Kemparaju K, et al. Hemininduced platelet activation and ferroptosis is mediated through ROSdriven proteasomal activity and inflammasome activation: Protection by Melatonin[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(9): 2303-16.] [DOI] [PubMed] [Google Scholar]
- 30.Wen Y, Chen H, Zhang L, et al. Glycyrrhetinic acid induces oxidative/nitrative stress and drives ferroptosis through activating NADPH oxidases and iNOS, and depriving glutathione in triplenegative breast cancer cells. Free Radic Biol Med. 2021;173:41–51. doi: 10.1016/j.freeradbiomed.2021.07.019. [Wen Y, Chen H, Zhang L, et al. Glycyrrhetinic acid induces oxidative/nitrative stress and drives ferroptosis through activating NADPH oxidases and iNOS, and depriving glutathione in triplenegative breast cancer cells[J]. Free Radic Biol Med, 2021, 173: 41-51.] [DOI] [PubMed] [Google Scholar]
